Combination of insulin-like growth factor-1, IGF binding protein-3, chromogranin A and prostate specific antigen can improve the detection of prostate cancer

Abstract

Aim: Prostate cancer (PCa) is the second most prevalent male cancer worldwide and designated the sixth most frequent male cancer in Arab countries. Although prostate specific antigen (PSA) has become the best and most valuable biomarker for screening of PCa, elevated levels of PSA can reflect the presence of malignant cells but can overlap with benign prostatic diseases. There is a necessity to develop and improve current tools for early detection and diagnosis of PCa. This study was done to evaluate the validation of serum insulin-like growth factor-1 (IGF-1), IGF binding protein-3 (IGFBP-3), chromogranin A (CgA) and combination with PSA in treatment of benign prostatic hyperplasia (BPH) and PCa patients.

Methods: The study included 72 patients with PCa, 70 BPH patients and 56 healthy male subjects of matched age. Full history and clinical data were recorded for all subjects.

Results: Serum PSA attained sensitivity of 84% at 82% specificity with an accuracy of 83%, although IGF-1, IGFBP-3 and CgA did not recognize PCa patients.

Conclusion: Combinations of IGF-1 and IGFBP-3 biomarkers with PSA were effectively differentiated between PCa and control groups as well as improving the overall value of sensitivity, specificity and diagnostic accuracy of PCa to 85% and 86% for IGF-1/PSA and IGFP-3/PSA respectively.

Keywords

Prostate cancer / benign prostatic hyperplasia / insulin-like growth factor-1 / IGF binding protein-3 / chromogranin A

References

[1] Cancer Facts and Figures 2017..2017;Atlanta, GAAmerican Cancer Society

[2] Mahmood A,Urcia JC.Tumor registry annual report 2011.2012;RiyadhKing Faisal Specialist Hospital and Research Center

[3] International Agency for Research on Cancer (IARC) (2012) [cited 2016 December 9]. Prostate Cancer, Estimated Incidence, Mortality and Prevalence Worldwide. Available from: http://globocan.iarc.fr/old/FactSheets/cancers/prostate-new.asp#INCIDENCE. [Last accessed on May 16, 2017]

[4] Siegel RL,Jemal A.Cancer statistics, 2017..CA Cancer J Clin2017;67:7-30

[5] Ramírez ML,Evans CP.Beyond prostate-specific antigen: alternate serum markers..Prostate Cancer Prostatic Dis2008;11:216-29

[6] Perkins GL,Sanders GK.Serum tumor markers..Am Fam Physician2003;68:1075-82

[7] Theodorescu D, Krupski TL (2009) [Cited 2016 December 12]. Prostate Cancer: Biology, Diagnosis, Pathology, Staging and Natural History. Available from: http://emedicine.medscape.com/article/458011-overview. [Last accessed on May 16, 2017]

[8] Bensalah K,Karam JA.New circulating biomarkers for prostate cancer..Prostate Cancer Prostatic Dis2008;11:112-20

[9] Stephan C,Hu X,Jung K.Prostate-specific antigen (PSA) screening and new biomarkers for prostate cancer (PCa)..EJIFCC2014;25:55-78

[10] Prensner JR,Wei JT.Beyond PSA: the next generation of prostate cancer biomarkers..Sci Transl Med2012;4:127rv3

[11] Weroha SJ.IGF system in cancer..Endocrinol Metab Clin North Am2012;41:335-50

[12] Moschos SJ.The role of the IGF system in cancer: from basic to clinical studies and clinical applications..Oncology2002;63:317-32

[13] Hamelers IH,Sipkema J,Steenbergh PH.Insulin-like growth factor I triggers nuclear accumulation of cyclin D1 in MCF-7S breast cancer cells..J Biol Chem2002;277:47645-52

[14] Wang H,Wang H,Zhang W.Insulin-like growth factor-binding protein 2 and 5 are differentially regulated in ovarian cancer of different histologic types..Mod Pathol2006;19:1149-56

[15] Luo SM,Deng WX,Luo JW.Expression of albumin, IGF-1, IGFBP-3 in tumor tissues and adjacent non-tumor tissues of hepatocellular carcinoma patients with cirrhosis..World J Gastroenterol2005;11:4272-6 PMCID:PMC4615458

[16] Rajaram S,Mohan S.Insulin-like growth factor-binding proteins in serum and other biological fluids: regulation and functions..Endocr Rev1997;18:801-31

[17] LeRoith D.The insulin like growth factor system and cancer..Cancer Lett2003;195:127-37

[18] Krishnan AV,Feldman D.The role of vitamin D in prostate cancer..Recent Results Cancer Res2003;164:205-21

[19] Papatsoris AG,Papavassiliou AG.Novel insights into the implication of the IGF-1 network in prostate cancer..Trends Mol Med2005;11:52-5

[20] Djavan B,Dulabon L,Farr A,Lepor H.Diagnostic strategies for prostate cancer..Eur Urol Suppl2011;10:26-37

[21] Berrigan D,Dodd KW,Lavigne J,Ballard-Barbash R.Race/ethnic variation in serum levels of IGF-I and IGFBP-3 in US adults..Growth Horm IGF Res2009;19:146-55 PMCID:PMC2702997

[22] Renehan AG,Minder C,Shalet SM.Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis..Lancet2004;363:1346-53

[23] Colombo B,Foglieni C,Arrigoni G.Chromogranin A expression in neoplastic cells affects tumor growth and morphogenesis in mouse models..Cancer Res2002;62:941-6

[24] Yang X,Li Z,Yang T,Liu L.Diagnostic value of circulating chromogranin a for neuroendocrine tumors: a systematic review and meta-analysis..PLoS One2015;10:e0124884

[25] Ferrero-Poüs M,Pecking A,Pichon MF.Serum chromogranin-A in advanced prostate cancer..BJU Int2001;88:790-6

[26] Berruti A,Mosca A,Mari M,Tarabuzzi R,Fontana D.Circulating neuroendocrine markers in patients with prostate carcinoma..Cancer2000;88:2590-7

[27] Fracalanza S,Pinto F,Sacco E,Plebani M,Basso D.Plasma chromogranin A in patients with prostate cancer improves the diagnostic efficacy of free/total prostate-specific antigen determination..Urol Int2005;75:57-61

[28] Grimaldi F,Barbina G,Trianni A,Zattoni F.The possible role of chromogranin A as a prognostic factor in organ-confined prostate cancer..Int J Biol Markers2006;21:229-34

[29] Ahlegren G,Lundberg S,Hugosson J.Neuroendocrine differentiation is not prognostic of failure after radical prostatectomy but correlates with tumor volume..Urology2000;56:1011-5

[30] Zitella A,Destefanis P,Torta M,Casetta G,Greco A,Aimo G,Tizzani A,Fontana D.Comparison between two commercially available chromogranin A assays in detecting neuroendocrine differentiation in prostate cancer and benign prostate hyperplasia..Clin Chim Acta2007;377:103-7

[31] Cohen P,Rosenfeld RG.The IGF axis in the prostate..Horm Metab Res1994;26:81-4

[32] Corrêa LL,Paiva HB,Cavallieri SA,Gadelha MR.Prostate cancer and acromegaly..Arq Bras Endocrinol Metabol2009;53:963-8

[33] Kehinde EO,Mojiminiyi OA,Daar AS.Putative role of serum insulin-like growth factor-1 (IGF-1) and IGF binding protein-3 (IGFBP-3) levels in the development of prostate cancer in Arab men..Prostate Cancer Prostatic Dis2005;8:84-90

[34] Djavan B,Seitz C.Insulin-like growth factors and prostate cancer..World J Urol2001;19:225-33

[35] Endogenous Hormones and Breast Cancer Collaborative Group,Appleby PN,Roddam AW.Insulin-like growth factor 1 (IGF1), IGF binding protein 3 (IGFBP3), and breast cancer risk: pooled individual data analysis of 17 prospective studies..Lancet Oncol2010;11:530-42

[36] Roddam AW,Appleby P,Ferrucci L,Metter EJ,Weiss NS,Hsing AW,Helzlsouer K,Riboli E,Janssen JA,Schröder FH,Pollak M,Schaefer C,Vogelman JH,English DR,Stattin P,Johansson M,Gann P,Holly JM,Meyer F,Galan P.Insulin-like growth factors, their binding proteins, and prostate cancer risk: analysis of individual patient data from 12 prospective studies..Ann Intern Med2008;149:461-71, W83-8

[37] Mikami K,Nakao M,Hayashi K,Mori M,Washio M,Suzuki K,Nakachi K,Ito Y,Tamakoshi A.Prostate cancer risk in relation to insulin-like growth factor (IGF)-I and IGF-binding protein-3: a nested case-control study in large scale cohort study in Japan..Asian Pac J Cancer Prev2009;10 Suppl:57-61

[38] Pham TM,Kikuchi S,Yatsuya H,Yoshimura T.A nested case-control study of stomach cancer and serum insulin-like growth factor (IGF)-1, IGF-2 and IGF-binding protein (IGFBP)-3..Eur J Cancer2007;43:1611-6

[39] Bonkhoff H.Neuroendocrine cells in benign and malignant prostate tissue: morphogenesis, proliferation, and androgen receptor status..Prostate Suppl1998;8:18-22

[40] Sciarpa A,Monti S,Mariotti G,D'Eramo G.Clinical under staging in patients with prostate adenocarcinoma submitted to radical prostatectomy: predictive value of serum chromogranin A..Prostate2004;58:421-8

[41] Appetecchia M,Pasimeni G,De Carli P,Barnabei A,Sperduti I.Incidence of high chromogranin A serum levels in patients with non-metastatic prostate adenocarcinoma..J Exp Clin Cancer Res2010;29:166 PMCID:PMC3018395

[42] Janssen JA,Ito K,Van Schaik RH,Pols HA,Schröder FH.Circulating free insulin-like growth factor (IGF)-I, total IGF-I, and IGF binding protein-3 levels do not predict the future risk to develop prostate cancer: results of a case-control study involving 201 patients within a population-based screening with a 4-year interval..J Clin Endocrinol Metab2004;89:4391-6

[43] Trojan L,Weiss C,Grobholz R,Michel MS.IGF-II serum levels increase discrimination between benign prostatic hyperplasia and prostate cancer and improve the predictive value of PSA in clinical staging..Eur Urol2006;49:286-92; discussion 292